Close

Explore AI

Explore GPTs

Explore AI News

Explore AI Videos

Explore AI for Jobs

Latest ImmunoPrecise Antibodies Ltd. AI Videos

Find the latest for ImmunoPrecise Antibodies Ltd. company videos

Follow
... 10:2
Palantir’s AI Dominance—Cathie Wood Says It’s Just Getting Started! Hedge Funds Are Piling Into PLTR

YT Finance

1+ months ago 1K views

Paler Technologies stands at the forefront of AI and data analytics, integrating cutting-edge solutions for enterprise and government operations. An exclusive event highlighted real-world case studies showcasing substantial returns on investment for clients. Despite its strong financial performance and recognition, concerns remain about high stock valuations, with analysts questioning the sustainability of its rapid growth. Key investor Kathy Wood from Arc Investment Management continues to express confidence in Paler's long-term potential amidst varying opinions on its current valuation and market strategy as it prepares for significant expansion in 2025.
05:48 - 05:53

Paler anticipates the widespread adoption of AI technology as a strategic advantage.

Palantir Big Data Analytics Finance
... 8:4
$AITX, the Hot AI Stock | CEO Steve Reinharz Showcases ROAMEO & RADDOG LE2!

AITX

1+ months ago 1K views

Steve Reinharz, CEO and CTO of Artificial Intelligence Technology Solutions, introduces innovative products like RADDOG LE2 and ROAMEO, highlighting features such as advanced mobility, obstacle avoidance, and human interaction capabilities. These products are designed to enhance safety and operational efficiency in various environments. Reinharz emphasizes the significant interest from Fortune 500 companies, underscoring the potential impact of their technologies in the market. The upcoming ISC West event is noted as a platform for further showcasing these advancements, with high expectations for customer engagement and demand.
02:48 - 03:14

ROAMEO Gen 4 incorporates advanced sensors and mobility features.

Artificial Intelligence Technology Solutions Robotics AI Startups
... 5:28
Smart Money Is LOADING Tempus AI

Fast Dollar

1+ months ago 1K views

Tempest AI has recently seen significant institutional buying despite a dip in its stock prices stemming from executive sell-offs. Major players like Kathy Wood, GP Morgan, and UBS are accumulating shares, indicating confidence in the company’s potential amidst broader market declines for tech stocks. The unique attributes of Tempest AI include its substantial involvement in AI applications in healthcare, such as diagnostics and drug discovery. While retail investors may panic, institutions appear to recognize a long-term opportunity, underscoring the importance of AI in future medicinal advancements.
Tempus AI Finance
... 9:26
The Role of AI in Personalized Medicine Tailoring Treatments for Every Patient

The Transforming Treatment Institute

1+ months ago 3K views

Personalized medicine, driven by advanced AI technologies, transforms healthcare by tailoring treatments to individual genetic profiles and environmental factors. This approach moves beyond one-size-fits-all practices, enabling predictive analytics for conditions such as heart disease and cancer. AI's power in genomics allows for faster and cheaper sequencing of DNA, assisting in early diagnosis and customized treatment plans. Future advancements promise a shift from reactive to proactive healthcare, empowering patients and doctors alike through continuous data monitoring and tailored interventions, ultimately enhancing survival rates and improving overall health outcomes.
02:38 - 02:42

Genomic profiling with AI identifies mutations for targeted cancer therapies.

Machine Learning Healthcare
... 11:45
$AITX, the Hot AI Stock – CEO Steve Reinharz Unveils All Mobile Security Robotics Breakthroughs!

AITX

1+ months ago 5K views

Artificial Intelligence Technology Solutions (AITX) has achieved significant advancements over the last 14 months, enhancing product offerings and team capabilities. The company is pioneering humanoid and robotic technologies like the Romeo V4 security guard and Rad Dog LE2, reflecting strong mobility and functionality. Upcoming product deployments and anticipated press coverage aim to drive market interest and sales. Efforts focus on improving current products rather than extensive R&D, with an expectation of impactful results for fiscal year 2026. Navigating production costs amidst tariff situations showcases resilience and flexibility in their operations.
05:11 - 05:14

Launched Rad Dog LE2 with improvements based on deployment feedback.

AITX Robotics AI Startups
... 13:50
IDOLpro: Generative AI for Chemistry | Tech talk with Amit Kadan

SandboxAQ

1+ months ago 2K views

IDOLpro combines AI and physics to enhance drug design by generating small molecules tailored for specific protein targets. Traditional methods are time-consuming, as they require evaluating vast chemical libraries. In contrast, IDOLpro uses generative AI to jump directly to relevant chemical spaces, optimizing for properties like synthetic accessibility and binding affinity. The framework employs a diffusion model guided by machine learning and physics-based scoring functions, significantly improving the efficiency of drug discovery. Initial evaluations show IDOLpro outperformed existing methods in generating viable drug candidates with desirable properties.
04:00 - 04:04

Iterative grading in IDOLpro enhances molecular properties like binding affinity.

SandboxAQ Machine Learning Research & Innovations
... 8:29
IPA Stock - AI Company to Watch (Update)

Blaze Capital

1+ months ago 10K views

Immuno Precise Antibodies (IPA), listed on NASDAQ as IPA, aims to revolutionize healthcare and drug discovery through its patented Lens AI technology. With over 90% of clinical drug developments failing, IPA addresses this challenge by accelerating drug discovery and integrating artificial intelligence with biological data. Their HFT patterns program introduces unique signature sequences, enabling the harmonization of complex biological data. The potential market for AI in drug discovery is projected to be worth $24.6 billion by 2029. The company is making strides in developing precision-targeted treatments, particularly for cancer, enhancing drug efficacy with fewer side effects.
04:01 - 04:06

In silico antibodies targeting tumor proteins show AI's efficacy in drug development.

Immunoprecise Antibodies Ltd Finance
... 22:14
This new AI finds REAL cancer cures & life-saving drugs

AI Search

1+ months ago 22K views

Google's new AI Co-Scientist has achieved significant breakthroughs in drug discovery, including new treatments for leukemia and liver disease, both validated in real-life experiments. This AI system, built with Gemini 2.0, assists scientists by generating novel hypotheses and research proposals, accelerating scientific discoveries. It collaboratively works with human scientists, providing original ideas for complex problems. The AI has demonstrated its capabilities by tackling issues like antibiotic resistance, suggesting candidates quickly compared to traditional research timelines, marking a transformative leap in biomedical research through advanced computational methods.
03:30 - 05:30

AI identifies new targets for liver fibrosis, demonstrating real-world efficacy.

Google Machine Learning Healthcare
... 22:14
This new AI finds REAL cancer cures & life-saving drugs

AI Search

1+ months ago 22K views

Google's new AI Co-Scientist has achieved significant breakthroughs in drug discovery, including new treatments for leukemia and liver disease, both validated in real-life experiments. This AI system, built with Gemini 2.0, assists scientists by generating novel hypotheses and research proposals, accelerating scientific discoveries. It collaboratively works with human scientists, providing original ideas for complex problems. The AI has demonstrated its capabilities by tackling issues like antibiotic resistance, suggesting candidates quickly compared to traditional research timelines, marking a transformative leap in biomedical research through advanced computational methods.
03:30 - 05:30

AI identifies new targets for liver fibrosis, demonstrating real-world efficacy.

Google Machine Learning Healthcare